Resources
15 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 8/4/2021 (updated 4/2/2024)
This session provided an opportunity to learn how to encourage faith leaders how to engage in harm reduction activities.
Posted 8/12/2020 (updated 3/28/2024)
The Recognizing and Addressing Rural Homeless in Opioid Use Disorder (OUD) Programs webinar took place Tuesday, August 04, 2020. The presentation and video recording are included.
Posted 8/11/2020 (updated 3/28/2024)
Corporation for Supportive Housing (CSH) developed a Racial Disparities and Disproportionality Index that looks at 16 unique systems and measures whether a racial and/or ethnic group’s representation in a particular public system is proportionate to, over or below their representation in the overall population and also allows for the examination of systematic differences between groups and geographies .
Posted 7/26/2023 (updated 3/28/2024)
Rural communities are finding innovative ways to combat dual crises: an affordable-housing shortage and the overdose and substance misuse epidemic. This presentation highlighted (1) federally subsidized housing regulations related to affordable housing for residents with a history of SUD and (2) cross-sector approaches to providing housing and support services to residents in recovery.
Posted 7/26/2023 (updated 3/28/2024)
This session discussed the barriers typically encountered and workarounds such as money, staff, and location. We encouraged participants to bring successes, near successes, and non-successes in expanding access over the last 3 years.
Posted 7/14/2023 (updated 3/28/2024)
The Centers for Disease Control and Prevention released data showing a significant increase – 276 percent in 21 jurisdictions from 2019 to 2022 – in overdose deaths involving Xylazine, a nonopioid sedative that’s been detected in illicitly manufactured fentanyl drug products.
Posted 6/18/2023 (updated 3/27/2024)
The Homeless and Housing Resource Center (HHRC) was established by SAMHSA to provide central hub of no-cost training on housing and treatment models.
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.
Posted 8/23/2022 (updated 3/27/2024)
This observational study of 719 612 pharmacy claims data shows that OOP costs of naloxone grew substantially beginning in 2016. However, OOP costs did not increase for all patients and all brands of naloxone but primarily for uninsured patients and for the Evzio brand. The findings suggest that the OOP cost of naloxone has been an increasingly substantial barrier to naloxone access for uninsured patients, a population that constitutes nearly one-fifth of adults with opioid use disorder.
Posted 7/25/2022 (updated 3/27/2024)
The interactive graphics allow readers to explore how the crisis of overdose deaths involving opioid use has not only grown in magnitude since 2000, but has also changed in character.